PHP
XENE icon

Parkman Healthcare Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Parkman Healthcare Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$28.9M Buy
497,035
+342,851
+222% +$15.8M 2.98% 7
2025
Q4 		$6.91M Sell
154,184
-21,953
-12% -$922K 0.66% 49
2025
Q3 		$7.07M Buy
176,137
+25,764
+17% +$907K 0.74% 50
2025
Q2 		$4.71M Sell
150,373
-24,203
-14% -$789K 0.54% 64
2025
Q1 		$5.86M Sell
174,576
-18,428
-10% -$700K 0.69% 47
2024
Q4 		$7.57M Buy
193,004
+1,346
+0.7% +$55.7K 1.01% 38
2024
Q3 		$7.55M Sell
191,658
-17,632
-8% -$711K 0.96% 39
2024
Q2 		$8.16M Sell
209,290
-14,652
-7% -$586K 1.09% 37
2024
Q1 		$9.64M Sell
223,942
-70,846
-24% -$3.26M 1.18% 33
2023
Q4 		$13.6M Buy
294,788
+78,144
+36% +$2.76M 1.91% 18
2023
Q3 		$7.4M Sell
216,644
-1,096
-0.5% -$41K 1.36% 24
2023
Q2 		$8.38M Sell
217,740
-59,543
-21% -$2.37M 1.45% 23
2023
Q1 		$9.92M Buy
277,283
+41,792
+18% +$1.54M 2.16% 12
2022
Q4 		$9.29M Buy
235,491
+12,894
+6% +$470K 2.47% 10
2022
Q3 		$8.04M Sell
222,597
-71,962
-24% -$2.59M 2.28% 12
2022
Q2 		$8.96M Sell
294,559
-9,627
-3% -$291K 3.3% 5
2022
Q1 		$9.3M Sell
304,186
-56,316
-16% -$1.69M 2.72% 10
2021
Q4 		$11.3M Buy
360,502
+49,295
+16% +$1.47M 2.49% 12
2021
Q3 		$4.75M Sell
311,207
-90,000
-22% -$1.56M 1.2% 26
2021
Q2 		$7.47M Buy
401,207
+26,812
+7% +$494K 1.63% 19
2021
Q1 		$6.7M Buy
374,395
+12,706
+4% +$215K 1.56% 21
2020
Q4 		$5.56M Sell
361,689
-103,136
-22% -$1.21M 1.43% 29
2020
Q3 		$5.15M Sell
464,825
-125,442
-21% -$1.48M 1.36% 32
2020
Q2 		$7.4M Hold
590,267
– – 2.09% 15
2020
Q1 		$6.69M Buy
590,267
+2,208
+0.4% +$31.4K 3.1% 8
2019
Q4 		$7.71M Buy
+588,059
New +$6.19M 2.23% 16

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Parkman Healthcare Partners's XENE Position: Q1 2026 in Review

Parkman Healthcare Partners increased its Xenon Pharmaceuticals (XENE) stake by 222% in Q1 2026, buying an estimated $15.8M and bringing the position to 497,035 shares worth $28.9M. The position accounts for 2.98% of the portfolio, ranked #7.

Parkman Healthcare Partners first reported a position in XENE in Q4 2019 and has held it in 26 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Parkman Healthcare Partners held 497,035 shares of Xenon Pharmaceuticals worth $28.9M as of Q1 2026.
  • Parkman Healthcare Partners bought 342,851 Xenon Pharmaceuticals shares in Q1 2026, an estimated $15.8M.
  • Xenon Pharmaceuticals made up 2.98% of Parkman Healthcare Partners's portfolio in Q1 2026, its #7 holding.
  • Parkman Healthcare Partners first reported a position in Xenon Pharmaceuticals in Q4 2019 and has held it in 26 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.